After modifications to the Indian patent system in 2005 made it possible to patent pharmaceutical items, the focus shifted to the development of novel medications. So, even though many Indian companies are investing heavily in pharmaceutical R&D, India is not yet an innovator's market. Strong FDI, mergers, and partnerships are occurring in India's pharmaceutical industry. The generics industry at home is eager to get into the lucrative international market. The number of ANDAs submitted to the FDA in the United States is likewise rising each year. There has been a shift in the industry's focus from the manufacturing of generic drugs to drug research and development. Following the 2019 release of the New Drugs and Clinical Trial Rules, the clinical testing sector has expanded fast, with many companies choosing India as a trial venue for their global Medicines. The commercial components of the sector are the primary focus of this research, which also suggests some changes to the existing business model and future directions.